Rxivist logo

Mitoxantrone modulates a glycosaminoglycan-spike complex to inhibit SARS-CoV-2 infection

By Qi Zhang, Peter Radvak, Juhyung Lee, Yue Xu, Vivian Cao-Dao, Miao Xu, Wei Zheng, Catherine Z Chen, Hang Xie, Yihong Ye

Posted 18 Oct 2021
bioRxiv DOI: 10.1101/2021.10.15.464595

Spike-mediated entry of SARS-CoV-2 into human airway epithelial cells is an attractive therapeutic target for COVID-19. In addition to protein receptors, the SARS-CoV-2 spike (S) protein also interacts with heparan sulfate, a negatively charged glycosaminoglycan (GAG) attached to certain membrane proteins on the cell surface. This interaction facilitates the engagement of spike with a downstream receptor to promote viral entry. Here, we show that Mitoxantrone, an FDA-approved topoisomerase inhibitor, targets a spike-GAG complex to compromise the fusogenic function of spike in viral entry. As a single agent, Mitoxantrone inhibits the infection of an authentic SARS-CoV-2 strain in a cell-based model and in human lung EpiAirway 3D tissues. Gene expression profiling supports the plasma membrane as a major target of Mitoxantrone but also underscores an undesired activity targeting nucleosome dynamics. We propose that Mitoxantrone analogs bearing similar GAG-binding activities but with reduced affinity for DNA topoisomerase may offer an alternative therapy to overcome breakthrough infections in the post-vaccine era.

Download data

  • Downloaded 205 times
  • Download rankings, all-time:
    • Site-wide: 146,351
    • In cell biology: 6,731
  • Year to date:
    • Site-wide: 66,435
  • Since beginning of last month:
    • Site-wide: 76,339

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide